-
Loading metrics
Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5
- Yoshitsugu Oikawa,
- Rumiko Izumi,
- Masashi Koide,
- Yoshihiro Hagiwara,
- Makoto Kanzaki,
- Naoki Suzuki,
- Koichi Kikuchi,
- Tetsuro Matsuhashi,
- Yukako Akiyama,
- Mariko Ichijo,
- Shun Watanabe,
- Takafumi Toyohara,
- Takehiro Suzuki,
- Eikan Mishima,
- Yasutoshi Akiyama,
- Yoshiaki Ogata,
- Chitose Suzuki,
- Hironori Hayashi,
- Eiichi N. Kodama,
- Ken-ichiro Hayashi,
- Eiji Itoi,
- Masashi Aoki,
- Shigeo Kure,
- [ ... ],
-
Takaaki Abe
Roles Data curation, Funding acquisition, Writing – original draft, Writing – review & editing
* E-mail: takaabe@med.tohoku.ac.jp
Affiliations Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan, Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Sendai, Japan, Department of Medical Science, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan
⨯ - [ view all ]
- [ view less ]
https://orcid.org/0000-0003-3170-4660
Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5
- Yoshitsugu Oikawa,
- Rumiko Izumi,
- Masashi Koide,
- Yoshihiro Hagiwara,
- Makoto Kanzaki,
- Naoki Suzuki,
- Koichi Kikuchi,
- Tetsuro Matsuhashi,
- Yukako Akiyama,
- Mariko Ichijo
x
- Published: December 2, 2020
- https://doi.org/10.1371/journal.pone.0231064